2025 Q3 -tulosraportti
Vain PDF
83 päivää sitten
Tarjoustasot
Määrä
Osto
485
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
15VWAP
Alin
13,76VaihtoMäärä
34 3 409 808
VWAP
Ylin
15Alin
13,76VaihtoMäärä
34 3 409 808
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 11.6.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenEbit and Eps are so bad that this stock only rises due to the big ai and tech stocks. This stock is a hype. For those who don't swing trade, watch out for your money.
·10 t sittenFirst, they must test and approve the medicine before it can be sold. Then, EBIT and EPS can be discussed.
·1 päivä sittenFDA pause lifted. That's why it's rising!
·20 t sittenI am predominantly positive on the case from here. The clinical hold appears more to be a regulatory bump than a structural problem, and the company has now clearly communicated focus on getting the TTR program resumed. At the same time, HAE phase 3 is running as planned with data later this year, and liquidity extends into 2027, so there is no acute capital pressure. I therefore believe that the stock can work its way up in the coming weeks/months, as the market gains more calm on the case and begins to price in the probability of positive phase 3. There will certainly be volatility, but the direction looks more up than down, if no negative news emerges.
·23.1.Those who sell now will probably regret it later on.·23.1.Agreed. The whole sector is in minus, just as it was in big plus yesterday. One must remember that it was at +13% yesterday- ·16.1.Latest news. https://finance.yahoo.com/news/jpm26-intellia-therapeutics-hopeful-crispr-155627347.html https://www.investing.com/news/company-news/cathie-woods-ark-adds-to-intellia-stock-holdings-on-january-15-93CH-4450972 https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-recently-143002798.html A little important info. (Positive)
·15.1.John Leonard said this at JPM on January 14 Yes, I mean, the patient – I mean, I can describe the clinical course, which I think is helpful for understanding. This is a patient who participated in the study, an 82-year-old man, who received the drug and just over three weeks later reported abdominal pain to his treating physician. His doctor said: “Go to the emergency room and they will look at you.” When he was there, it was observed that he had elevated transaminases. He was admitted to the hospital for observation. During the time he was hospitalized – and the hospital, as far as we can tell, took excellent care of him – the medical staff gave him, among other things, steroids. Approximately one week into his hospital stay, his condition deteriorated, he was evaluated, and free air was found in his abdomen. He underwent surgery and a perforation of approximately five centimeters (two inches) was found in the duodenum, connected to a duodenal ulcer that was also discovered. The patient never really recovered from this. He subsequently had a very stormy course, with episodes of hypoperfusion, septicemia, and ultimately the family chose to withdraw life support. He did not die of liver failure, which I believe has been misunderstood by some observers here. It is highly unlikely, in our assessment, that what the patient experienced in the form of liver damage, as manifested by elevated transaminases, was attributable to the other underlying process. The death was ultimately attributed to sepsis resulting from the perforated ulcer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
Vain PDF
83 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenEbit and Eps are so bad that this stock only rises due to the big ai and tech stocks. This stock is a hype. For those who don't swing trade, watch out for your money.·10 t sittenFirst, they must test and approve the medicine before it can be sold. Then, EBIT and EPS can be discussed.
- ·1 päivä sittenFDA pause lifted. That's why it's rising!·20 t sittenI am predominantly positive on the case from here. The clinical hold appears more to be a regulatory bump than a structural problem, and the company has now clearly communicated focus on getting the TTR program resumed. At the same time, HAE phase 3 is running as planned with data later this year, and liquidity extends into 2027, so there is no acute capital pressure. I therefore believe that the stock can work its way up in the coming weeks/months, as the market gains more calm on the case and begins to price in the probability of positive phase 3. There will certainly be volatility, but the direction looks more up than down, if no negative news emerges.
- ·23.1.Those who sell now will probably regret it later on.·23.1.Agreed. The whole sector is in minus, just as it was in big plus yesterday. One must remember that it was at +13% yesterday
- ·16.1.Latest news. https://finance.yahoo.com/news/jpm26-intellia-therapeutics-hopeful-crispr-155627347.html https://www.investing.com/news/company-news/cathie-woods-ark-adds-to-intellia-stock-holdings-on-january-15-93CH-4450972 https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-recently-143002798.html A little important info. (Positive)
- ·15.1.John Leonard said this at JPM on January 14 Yes, I mean, the patient – I mean, I can describe the clinical course, which I think is helpful for understanding. This is a patient who participated in the study, an 82-year-old man, who received the drug and just over three weeks later reported abdominal pain to his treating physician. His doctor said: “Go to the emergency room and they will look at you.” When he was there, it was observed that he had elevated transaminases. He was admitted to the hospital for observation. During the time he was hospitalized – and the hospital, as far as we can tell, took excellent care of him – the medical staff gave him, among other things, steroids. Approximately one week into his hospital stay, his condition deteriorated, he was evaluated, and free air was found in his abdomen. He underwent surgery and a perforation of approximately five centimeters (two inches) was found in the duodenum, connected to a duodenal ulcer that was also discovered. The patient never really recovered from this. He subsequently had a very stormy course, with episodes of hypoperfusion, septicemia, and ultimately the family chose to withdraw life support. He did not die of liver failure, which I believe has been misunderstood by some observers here. It is highly unlikely, in our assessment, that what the patient experienced in the form of liver damage, as manifested by elevated transaminases, was attributable to the other underlying process. The death was ultimately attributed to sepsis resulting from the perforated ulcer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
485
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
15VWAP
Alin
13,76VaihtoMäärä
34 3 409 808
VWAP
Ylin
15Alin
13,76VaihtoMäärä
34 3 409 808
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 11.6.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 |
2025 Q3 -tulosraportti
Vain PDF
83 päivää sitten
Uutiset
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| Vuosittainen yhtiökokous 2025 | 11.6.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenEbit and Eps are so bad that this stock only rises due to the big ai and tech stocks. This stock is a hype. For those who don't swing trade, watch out for your money.·10 t sittenFirst, they must test and approve the medicine before it can be sold. Then, EBIT and EPS can be discussed.
- ·1 päivä sittenFDA pause lifted. That's why it's rising!·20 t sittenI am predominantly positive on the case from here. The clinical hold appears more to be a regulatory bump than a structural problem, and the company has now clearly communicated focus on getting the TTR program resumed. At the same time, HAE phase 3 is running as planned with data later this year, and liquidity extends into 2027, so there is no acute capital pressure. I therefore believe that the stock can work its way up in the coming weeks/months, as the market gains more calm on the case and begins to price in the probability of positive phase 3. There will certainly be volatility, but the direction looks more up than down, if no negative news emerges.
- ·23.1.Those who sell now will probably regret it later on.·23.1.Agreed. The whole sector is in minus, just as it was in big plus yesterday. One must remember that it was at +13% yesterday
- ·16.1.Latest news. https://finance.yahoo.com/news/jpm26-intellia-therapeutics-hopeful-crispr-155627347.html https://www.investing.com/news/company-news/cathie-woods-ark-adds-to-intellia-stock-holdings-on-january-15-93CH-4450972 https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-recently-143002798.html A little important info. (Positive)
- ·15.1.John Leonard said this at JPM on January 14 Yes, I mean, the patient – I mean, I can describe the clinical course, which I think is helpful for understanding. This is a patient who participated in the study, an 82-year-old man, who received the drug and just over three weeks later reported abdominal pain to his treating physician. His doctor said: “Go to the emergency room and they will look at you.” When he was there, it was observed that he had elevated transaminases. He was admitted to the hospital for observation. During the time he was hospitalized – and the hospital, as far as we can tell, took excellent care of him – the medical staff gave him, among other things, steroids. Approximately one week into his hospital stay, his condition deteriorated, he was evaluated, and free air was found in his abdomen. He underwent surgery and a perforation of approximately five centimeters (two inches) was found in the duodenum, connected to a duodenal ulcer that was also discovered. The patient never really recovered from this. He subsequently had a very stormy course, with episodes of hypoperfusion, septicemia, and ultimately the family chose to withdraw life support. He did not die of liver failure, which I believe has been misunderstood by some observers here. It is highly unlikely, in our assessment, that what the patient experienced in the form of liver damage, as manifested by elevated transaminases, was attributable to the other underlying process. The death was ultimately attributed to sepsis resulting from the perforated ulcer.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
485
Myynti
Määrä
300
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
15VWAP
Alin
13,76VaihtoMäärä
34 3 409 808
VWAP
Ylin
15Alin
13,76VaihtoMäärä
34 3 409 808
Välittäjätilasto
Dataa ei löytynyt